ClinicalTrials.gg
CompletedNCT04152083RELIEFUpdated Aug 17, 2021Results posted

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

A Phase 3 interventional study of Eptinezumab and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 57 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
8th of 21
485 · median 193
Started
2019
the only one that year
Phase 3
13 of 21
5 open now
Registered
7th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 8th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.

Read the detailed description

This will be a parallel group, double-blind, randomized, placebo-controlled study assessing the efficacy of eptinezumab for acute migraine, defined as an active intercurrent migraine occurring in those participants who are candidates for preventive therapy. Participants will be randomized to receive a single dose of eptinezumab or placebo in a 1:1 ratio. The total study duration will be approximately 4 to 12 weeks, including up to an 8-week screening period and 4-week of safety follow-up, with clinic visits occurring on Screening, Day 0 (dosing day), and Week 4.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Greater than 1-year history of migraine, with or without aura, with onset of first migraine before age 50.
  • Migraine on 4 to 15 days per month in the 3 months prior to screening.
  • Headache free for at least 24 hours prior to onset of a qualifying migraine.

Exclusion criteria

Exclusion Criteria:

  • Unable to differentiate migraine from other headache or pain disorders.
  • Use of the following medication, for any indication, within the 24-hour period prior to dosing with study drug:

    1. triptans, ergotamines and ergot-derivatives
    2. analgesics (including but not limited to acetaminophen, tramadol, nonsteroidal anti-inflammatory drugs [NSAIDs], combination analgesics, caffeine-containing analgesics, and opioids/narcotics) and other acute migraine medication(s)
    3. antiemetic medications (including but not limited to prochlorperazine, promethazine, droperidol, chlorpromazine, metoclopramide)
    4. antihistamines
    5. devices, neuromodulation, neurostimulation, or injectable therapy (trigger point injections, extracranial nerve blocks, facet joint injections, spinal manipulation)
  • Use of the following medication, for any indication, in each of the 3 months prior to screening:

    1. opioids/narcotics or butalbital containing products (including combinations) on more than 4 days per month;
    2. triptans, ergotamines, or combination analgesics for 10 or more days per month;
    3. acetaminophen, aspirin or NSAIDs for 15 or more days per month (except if participant is taking 81 mg dose of aspirin for cardiac prophylaxis)
  • History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine and migraine with neurological accompaniments that are not typical of migraine aura (for example, diplopia, altered consciousness, or long duration).
  • Any changes to preventive migraine treatment(s) within 1 month prior to screening and up to treatment with the study drug (Day 0).
  • Any use of approved devices, neuromodulation, neurostimulation, or injectable therapy (trigger point injections, extracranial nerve blocks, facet joint injections) within the 24-hour period prior to treatment with study drug (Day 0).
  • Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 7 days prior to treatment with study drug (Day 0).
  • Any use of systemic for migraine or any other reason within 3 months prior to treatment with study drug (Day 0).
  • Evidence or medical history of psychiatric diseases that are uncontrolled and/or untreated.
  • Receipt of any monoclonal antibody treatment, for migraine or any other indication, (within or outside a clinical study) within 6 months prior to screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    Eptinezumab

    Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.

    Drug: Eptinezumab

  • Placebo comparator
    Placebo

    Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.

    Drug: Placebo

Interventions

  • Injection for IV administration

  • DrugPlacebo

    Injection for IV administration

06

What researchers measure

Primary outcomes

  1. Time to Headache Pain Freedom

    Time to headache pain freedom defined as the time that the participant reported freedom of pain, meaning their headache pain had gone from moderate to severe at baseline to no pain.

    Time frame: Up to 48 hours postdose

  2. Time to Absence of Most Bothersome Symptom (MBS)

    Time to absence of most bothersome symptom defined as the time that the participant reported absence of MBS (of nausea, photophobia, or phonophobia).

    Time frame: Up to 48 hours postdose

Secondary outcomes

  1. Headache Pain Freedom at 2 Hours

    Number of participants with freedom from headache pain at 2 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.

    Time frame: 2 hours

  2. Absence of MBS at 2 Hours

    Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 2 hours postdose are reported.

    Time frame: 2 hours

  3. Headache Pain Freedom at 4 Hours

    Number of participants with freedom from headache pain at 4 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.

    Time frame: 4 hours

  4. Absence of MBS at 4 Hours

    Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 4 hours postdose are reported.

    Time frame: 4 hours

  5. Use of Rescue Medication Within the First 24 Hours

    Rescue medication was defined as any medication to treat migraine or migraine-associated symptoms, which could have been provided to the participant any time after 2 hours post-start of infusion. Use of rescue medication was captured in the eDiary. Number of participants who used rescue medication up to 24 hours postdose are reported.

    Time frame: Up to 24 hours postdose

07

Results

Posted Aug 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneEptinezumabPlacebo
Started241244
Received at least 1 dose of study drug238242
Completed235241
Not completed63
Withdrew: Lost to follow-up21
Withdrew: Adverse event10
Withdrew: Randomized but not treated32

Outcome measures

PrimaryTime to Headache Pain Freedom

Time to headache pain freedom defined as the time that the participant reported freedom of pain, meaning their headache pain had gone from moderate to severe at baseline to no pain.

Time frame:
Up to 48 hours postdose
Reported as:
Median · hours
Time to Headache Pain Freedom
hoursEptinezumabPlacebo
Time to Headache Pain Freedom4.0 (2.5 to 12.0)9.0 (3.0 to 48.0)
Statistical analysis
  • Eptinezumab vs Placebo · Likelihood ratio test · p = 0.0006 (Threshold for significance at 0.05 level.) · Hazard ratio (hr): 1.54 · 95% CI 1.20 to 1.98
PrimaryTime to Absence of Most Bothersome Symptom (MBS)

Time to absence of most bothersome symptom defined as the time that the participant reported absence of MBS (of nausea, photophobia, or phonophobia).

Time frame:
Up to 48 hours postdose
Reported as:
Median · hours
Time to Absence of Most Bothersome Symptom (MBS)
hoursEptinezumabPlacebo
Time to Absence of Most Bothersome Symptom (MBS)2.0 (1.0 to 3.5)3.0 (1.5 to 12.0)
Statistical analysis
  • Eptinezumab vs Placebo · Likelihood ratio test · p = <0.0001 (Threshold for significance at 0.05 level.) · Hazard ratio (hr): 1.75 · 95% CI 1.41 to 2.19
SecondaryHeadache Pain Freedom at 2 Hours

Number of participants with freedom from headache pain at 2 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.

Time frame:
2 hours
Reported as:
Count of participants · Participants
Headache Pain Freedom at 2 Hours
ParticipantsEptinezumabPlacebo
Headache Pain Freedom at 2 Hours5629
Statistical analysis
  • Eptinezumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0009 (Threshold for significance at 0.05 level.) · Odds ratio (or): 2.27 · 95% CI 1.39 to 3.72
SecondaryAbsence of MBS at 2 Hours

Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 2 hours postdose are reported.

Time frame:
2 hours
Reported as:
Count of participants · Participants
Absence of MBS at 2 Hours
ParticipantsEptinezumabPlacebo
Absence of MBS at 2 Hours13286
Statistical analysis
  • Eptinezumab vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 2.25 · 95% CI 1.55 to 3.25
SecondaryHeadache Pain Freedom at 4 Hours

Number of participants with freedom from headache pain at 4 hours postdose are reported. Freedom from headache pain meaning that the headache pain that had gone from moderate to severe at baseline to no pain with no administration of rescue medications.

Time frame:
4 hours
Reported as:
Count of participants · Participants
Headache Pain Freedom at 4 Hours
ParticipantsEptinezumabPlacebo
Headache Pain Freedom at 4 Hours11164
SecondaryAbsence of MBS at 4 Hours

Number of participants with absence of MBS (of nausea, photophobia, or phonophobia) at 4 hours postdose are reported.

Time frame:
4 hours
Reported as:
Count of participants · Participants
Absence of MBS at 4 Hours
ParticipantsEptinezumabPlacebo
Absence of MBS at 4 Hours15590
SecondaryUse of Rescue Medication Within the First 24 Hours

Rescue medication was defined as any medication to treat migraine or migraine-associated symptoms, which could have been provided to the participant any time after 2 hours post-start of infusion. Use of rescue medication was captured in the eDiary. Number of participants who used rescue medication up to 24 hours postdose are reported.

Time frame:
Up to 24 hours postdose
Reported as:
Count of participants · Participants
Use of Rescue Medication Within the First 24 Hours
ParticipantsEptinezumabPlacebo
Use of Rescue Medication Within the First 24 Hours75145

Adverse events

Collected over Start of treatment (Day 0) through end of study (Week 4). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eptinezumab0/238 (0%)0/238 (0%)5/238 (2.1%)
Placebo0/242 (0%)0/242 (0%)0/242 (0%)
Most frequent other events
Most frequent other events
EventEptinezumabPlacebo
HypersensitivityImmune system disorders5/2380/242

Baseline characteristics

Safety population included all participants who received eptinezumab or placebo.

Age, Continuous
Age, Continuous(years)EptinezumabPlaceboTotal
Mean44.9 ± 11.9944.1 ± 12.1244.5 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)EptinezumabPlaceboTotal
Female202201403
Male364177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EptinezumabPlaceboTotal
Hispanic or Latino293160
Not Hispanic or Latino209211420
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EptinezumabPlaceboTotal
Race — White200213413
Race — Black or African American301949
Race — Asian235
Race — American Indian or Alaska Native213
Race — Native Hawaiian or other Pacific Islander112
Race — Other011
Race — Multiple347
Number of Migraine Days/Month
Number of Migraine Days/Month(days/month)EptinezumabPlaceboTotal
Mean7.2 ± 2.657.2 ± 2.567.2 ± 2.60
Number of Participants With Most Bothersome Symptoms (MBS)
Number of Participants With Most Bothersome Symptoms (MBS)(participants)EptinezumabPlaceboTotal
Photophobia114114228
Nausea7879157
Phonophobia464793
Missing022
08

Study locations

57 sites
  • Alabama Clinical Therapeutics
    Birmingham, Alabama 35235, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • The Neurology Center of Southern California - Carlsbad
    Carlsbad, California 92011, United States
  • Excell research Inc
    Oceanside, California 92056, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Denver Neurological Clinic - Denver
    Denver, Colorado 80210, United States
  • Coastal Connecticut Research LLC
    New London, Connecticut 06320, United States
  • Ki Health Partners LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • The George Washington Medical Faculty Associates
    Washington, District of Columbia 20052, United States
  • Medicinae Doctor Clinical
    Hallandale Beach, Florida 33009, United States
  • AGA Clinical trials
    Hialeah, Florida 33012, United States
  • Meridien Research - Maitland
    Maitland, Florida 32751, United States
  • Palm Beach Neurology and Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Office of Doctor Frank Berenson
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research - Savannah Neurology Specialists
    Savannah, Georgia 31405, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • College Park Family Care Center Physicians
    Overland Park, Kansas 66212, United States
  • Phoenix Medical Research
    Prairie Village, Kansas 66208, United States
  • Central Kentucky Research Associates
    Lexington, Kentucky 40509, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • MedVadis Research Corporation, LLC
    Waltham, Massachusetts 02451, United States
  • Michigan Head Pain and Neurological institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute - Minneapolis
    Minneapolis, Minnesota 55402, United States
  • Headache Neurology Research Institute
    Ridgeland, Mississippi 39157, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research
    Springfield, Missouri 65810, United States
  • Nevada Headache Institute
    Las Vegas, Nevada 89113, United States
  • Albuqerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Dent Neurologic Institute - Amherst
    Amherst, New York 14226, United States
  • Integrative Clinical Trials
    Brooklyn, New York 11229, United States
  • CTI Clinical Research center
    Cincinnati, Ohio 45212, United States
  • Aventiv Research - Columbus
    Columbus, Ohio 43213, United States
  • Hometown Urgent Care And Research - Huber Heights
    Dayton, Ohio 45424, United States
  • Neuro-Behavioral Clinical Research Inc
    North Canton, Ohio 44720, United States
  • Delricht Research
    Tulsa, Oklahoma 74133, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Frontier Clinical Rsearch LLC
    Smithfield, Pennsylvania 15478, United States
  • Coastal Carolina Research Center - Mount Pleasant
    Mount Pleasant, South Carolina 29464, United States
  • Chattanooga Medical research LLC
    Chattanooga, Tennessee 37404, United States
  • WR-ClinSearch LLC
    Chattanooga, Tennessee 37421, United States
  • Holston Medical Group - Kingsport
    Kingsport, Tennessee 37660, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Texas Center for Drug Development Inc
    Houston, Texas 77081, United States
  • Ventavia Research Group, LLC
    Keller, Texas 76248, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Neuroscience Group
    Neenah, Wisconsin 54956, United States
  • Ltd "Acad Fridon Todua Medical Center - Ltd Research Institute of Clinical Medicine"
    Tbilisi, Georgia
  • Ltd "Aversi Clinic"
    Tbilisi, Georgia
  • Ltd "Multiprofile Clinica Consilium Medulla"
    Tbilisi, Georgia
  • Ltd Simon Khechinashvili University Clinic
    Tbilisi, Georgia
  • td "Israel-Georgia Medical Research Clinic Helsicore"
    Tbilisi, Georgia
09

References and documents

Publications

  • Cady R, Lipton RB, Buse DC, Josiassen MK, Lindsten A, Ettrup A. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study. J Headache Pain. 2022 Jul 28;23(1):91. doi: 10.1186/s10194-022-01463-3. PubMed 35902796 ↗
  • Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC Neurol. 2022 Jun 3;22(1):205. doi: 10.1186/s12883-022-02714-1. Erratum In: BMC Neurol. 2023 Sep 6;23(1):318. doi: 10.1186/s12883-023-03368-3. PubMed 35659622 ↗
  • McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain. 2022 Feb 7;23(1):22. doi: 10.1186/s10194-021-01376-7. PubMed 35130832 ↗
  • Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA. 2021 Jun 15;325(23):2348-2356. doi: 10.1001/jama.2021.7665. PubMed 34128999 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jul 2020, 8 months.

Results were first posted in Aug 2021, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 8 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2019
First posted
Nov 5, 2019
StartActual
Nov 7, 2019
Primary completionActual
Jul 8, 2020
CompletionActual
Jul 8, 2020
Results first posted
Aug 16, 2021
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04152083
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Nov 7, 2019
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020
Results posted
Aug 16, 2021
Last update
Aug 17, 2021

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion